Gregory Renza
Stock Analyst at RBC Capital
(3.18)
# 1,177
Out of 4,981 analysts
207
Total ratings
40.31%
Success rate
3.36%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Outperform | $31 → $35 | $65.62 | -46.66% | 3 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $26 | $23.61 | +10.12% | 16 | May 19, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $3.31 | +141.69% | 12 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $5 | $2.38 | +110.08% | 11 | May 14, 2025 | |
| EXEL Exelixis | Reiterates: Outperform | $40 | $39.15 | +2.17% | 10 | May 14, 2025 | |
| ONC BeOne Medicines AG | Maintains: Outperform | $312 → $311 | $324.34 | -4.11% | 2 | May 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $182 → $172 | $126.16 | +36.33% | 14 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $7.05 | +353.90% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $276.39 | +15.78% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $33.40 | +103.59% | 3 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $15 | $3.48 | +331.03% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $12.94 | -7.26% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.72 | +44.03% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $32 | $8.60 | +272.09% | 9 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $9.05 | +198.34% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $24.63 | +147.67% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $27.12 | -33.63% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $2.43 | +1,875.31% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $3.14 | +218.47% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $5.57 | +79.53% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $18.87 | +149.14% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $36.77 | +55.02% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $7.02 | -43.02% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $4.83 | +314.08% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $6.03 | +165.34% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $10.66 | +1,589.35% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.54 | +5,081.35% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.68 | +4,295.60% | 3 | Jun 2, 2020 |
Cidara Therapeutics
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $65.62
Upside: -46.66%
ACADIA Pharmaceuticals
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $23.61
Upside: +10.12%
ADC Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.31
Upside: +141.69%
Inovio Pharmaceuticals
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $2.38
Upside: +110.08%
Exelixis
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $39.15
Upside: +2.17%
BeOne Medicines AG
May 8, 2025
Maintains: Outperform
Price Target: $312 → $311
Current: $324.34
Upside: -4.11%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $126.16
Upside: +36.33%
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $7.05
Upside: +353.90%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $276.39
Upside: +15.78%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $33.40
Upside: +103.59%
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $3.48
Upside: +331.03%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $12.94
Upside: -7.26%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $9.72
Upside: +44.03%
Feb 27, 2025
Maintains: Outperform
Price Target: $34 → $32
Current: $8.60
Upside: +272.09%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $9.05
Upside: +198.34%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $24.63
Upside: +147.67%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $27.12
Upside: -33.63%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $2.43
Upside: +1,875.31%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $3.14
Upside: +218.47%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $5.57
Upside: +79.53%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $18.87
Upside: +149.14%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $36.77
Upside: +55.02%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $7.02
Upside: -43.02%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $4.83
Upside: +314.08%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $6.03
Upside: +165.34%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $10.66
Upside: +1,589.35%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.54
Upside: +5,081.35%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.68
Upside: +4,295.60%